Ionis Pharmaceuticals (IONS) is back in focus after its latest quarterly report showed revenue of US$267.95 million and a swing from a prior profit to a net loss of US$114.65 million.

The recent earnings miss and guidance update appear to have shifted sentiment, with Ionis Pharmaceuticals’ share price down 36.88% over the past month and 31.61% year to date, even though the 1 year total shareholder return is 32.74%. This points to fading short term momentum alongside a still positive longer term picture.

If this kind of volatility has you looking wider across healthcare, it could be worth scanning other opportunities in AI driven drug development through our healthcare AI stock screener 42 healthcare AI stocks

Ionis Pharmaceuticals has fallen hard after its latest quarter, even though longer term returns remain positive. That sets up a clear fork for investors: Is the recent pullback enough of a reset, or is patience wiser before committing new capital?

Most Popular Narrative: 40.8% Undervalued

Ionis Pharmaceuticals last closed at $54.49, while the most followed narrative anchors fair value at $92.00. That gap rests on a very specific growth and profitability story.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.

Expanding addressable patient populations, from rare diseases to larger segments such as severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, is described as positioning Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

Want to see what underpins that confidence in Ionis Pharmaceuticals? The core narrative hangs on rapid top line expansion, rising margins, and a richer earnings profile that supports a much higher future multiple.

Result: Fair Value of $92.00 (UNDERVALUED)

However, Ionis Pharmaceuticals still faces real tests, including execution risk around late stage approvals and the possibility that pricing pressure in broader indications could squeeze margins.

Another View On Ionis Pharmaceuticals Valuation

The first narrative leans heavily on future growth and analyst targets to frame Ionis Pharmaceuticals as 40.8% undervalued at a fair value of $92.00. Yet on a simple P/S basis the picture is less generous. Ionis trades at 10.4x sales, almost double its own fair ratio of 4.5x and above peer averages outside biotech. That kind of gap raises a practical question for you as an investor: Is the current price already baking in much of the long term story?

Our P/S based work highlights how sensitive Ionis Pharmaceuticals could be if sentiment or growth expectations soften, since a move toward the 4.5x fair ratio would imply a much lower implied value. At the same time the stock sits slightly cheaper than the US Biotechs industry at 11.5x P/S, which some investors may see as room for upside if the growth case plays out. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment around Ionis Pharmaceuticals is clearly split, so it helps to move fast and review the numbers yourself before opinions harden. To see what investors are optimistic about, take a closer look at the 3 key rewards

Looking for more investment ideas beyond Ionis Pharmaceuticals?

If Ionis Pharmaceuticals has you thinking about what else could be worth your attention, use the Simply Wall St screener to spot opportunities before they move away.

• Target potential bargains early by reviewing companies that appear mispriced on quality and valuation through the 51 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with strong finances using the solid balance sheet and fundamentals stocks screener (49 results).
• Get ahead of the crowd by searching for lesser known opportunities with solid fundamentals via the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.